Alkermes Plans Separating Its Oncology Unit; Lifts FY22 Earnings Guidance

Vandana Singh
1 min read
0
In this article:

  • Alkermes plc (NASDAQ: ALKS) is exploring separating its commercial-stage neuroscience and development-stage oncology business as part of an ongoing review of strategic alternatives for the oncology business.

  • Alkermes will retain its focus on neuroscience and drive its proprietary commercial product growth.

  • The company will also focus on advancing the development of pipeline programs focused on neurological disorders, including ALKS 2680, an orexin 2 receptor agonist for narcolepsy.

  • The oncology business would continue to focus on the discovery and development of cancer therapies, including the continued development of nemvaleukin alfa (nemvaleukin).

  • Nemvaleukin is currently in potential registration enabling studies in two difficult-to-treat tumor types: platinum-resistant ovarian cancer and mucosal melanoma.

  • The separation, if consummated, is expected to be completed in the second half of 2023. The facilities, research & manufacturing operations in Wilmington, Ohio, and Athlone, Ireland, will remain with Alkermes.

  • The company reported Q3 sales of $252.4 million, compared to $294.1 million a year ago, missing the consensus of $271.41 million.

  • It reported an adjusted EPS of $0.02, below the consensus of $0.03.

  • Alkermes tightened FY22 guidance to $1.07–$1.12 billion from $1.05–$1.12 billion versus the consensus of $1.10 billion.

  • It forecasts adjusted EPS of $0.15 – $0.33, up from $0.09 – $0.27 and the consensus of $0.20.

  • Price Action: ALKS shares are trading higher by 2.11% at $23.75 on the last check Wednesday.

  • Photo Via Company

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories